Myelodysplasia: battle in the bone marrow.
Nature medicine. . NIHMSID: NIHMS607880.
Progress in determining response to treatment in gastrointestinal stromal tumor.
Expert review of anticancer therapy. . NIHMSID: NIHMS1628621.
Hypoxia-driven oncometabolite L-2HG maintains stemness-differentiation balance and facilitates immune evasion in pancreatic cancer.
Cancer research. . NIHMSID: NIHMS1727368.
Combined MEK and STAT3 Inhibition Uncovers Stromal Plasticity by Enriching for Cancer-Associated Fibroblasts With Mesenchymal Stem Cell-Like Features to Overcome Immunotherapy Resistance in Pancreatic Cancer.
Gastroenterology. . NIHMSID: NIHMS1893587.
46213 Florida Community-Engaged Research Alliance Against COVID-19 in Disproportionately Affected Communities (FL-CEAL): addressing education, awareness, access, and inclusion of underserved communities in COVID-19 research.
Journal of clinical and translational science. . NIHMSID: NIHMS1895855.doi: 10.1017/cts.2021.609.
All-in-One Pyruvate Dehydrogenase Kinase Inhibitor for Tracking, Targeting, and Enhanced Efficacy.
Bioconjugate chemistry. . NIHMSID: NIHMS1968905.
Inhibition of platelet aggregation by 5-nitro-2-furaldehyde diacetate with observations on structure-activity relationships.
J Lab Clin Med.
1976 Apr;87(4):703-9. PubMed PMID:
1270881.
Regulation of expression of human granulocyte/macrophage colony-stimulating factor.
Proc Natl Acad Sci U S A.
1986 Nov;83(22):8669-73. doi: 10.1073/pnas.83.22.8669. PubMed PMID:
3490669; PubMed Central PMCID:
PMC386992.
The expression and target cell specificity of human granulocyte-macrophage colony-stimulating factor.
Year Immunol.
1988;3:144-51. Review. PubMed PMID:
2831680.
Characterization of the human granulocyte-macrophage colony-stimulating factor promoter region by genetic analysis: correlation with DNase I footprinting.
Mol Cell Biol.
1988 May;8(5):1979-84. doi: 10.1128/mcb.8.5.1979-1984.1988. PubMed PMID:
2838738; PubMed Central PMCID:
PMC363376.
Serum cholesterol-lowering activity of granulocyte-macrophage colony-stimulating factor.
JAMA.
1988 Dec 9;260(22):3297-300. PubMed PMID:
3054191.
Treatment of refractory aplastic anemia with recombinant human granulocyte-macrophage-colony-stimulating factor.
Blood.
1989 Feb 15;73(3):694-9. PubMed PMID:
2644986.
Activation of the GM-CSF promoter by HTLV-I and -II tax proteins.
Oncogene.
1989 Jun;4(6):671-6. PubMed PMID:
2660069.
Multiple mechanisms control the expression of granulocyte-macrophage colony-stimulating factor by human fibroblasts.
J Immunol.
1989 Oct 1;143(7):2374-7. PubMed PMID:
2674282.
Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome.
J Clin Oncol.
1989 Nov;7(11):1637-45. doi: 10.1200/JCO.1989.7.11.1637. PubMed PMID:
2809680.
Effects of recombinant human granulocyte-macrophage colony-stimulating factor as treatment for aplastic anemia and agranulocytosis.
Prog Clin Biol Res.
1990;338:143-50. PubMed PMID:
2189137.
Human granulocyte-macrophage colony-stimulating factor (GM-CSF): regulation of expression.
Prog Clin Biol Res.
1990;338:27-41. Review. PubMed PMID:
2189139.
Therapeutic use of hematopoietic growth factors in bone marrow transplantation.
Cancer Treat Res.
1990;50:141-64. doi: 10.1007/978-1-4613-1493-6_9. Review. PubMed PMID:
1976348.
Successful treatment of hepatic venoocclusive disease in a bone marrow transplant patient with orthotopic liver transplantation.
Transplantation.
1990 Apr;49(4):819-21. PubMed PMID:
2326879.
Bone marrow transplantation for severe aplastic anemia. Effect of a preparative regimen of cyclophosphamide-low-dose total-lymphoid irradiation and posttransplant cyclosporine-methotrexate therapy.
Transplantation.
1990 Apr;49(4):720-4. PubMed PMID:
2326866.
Postremission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment.
J Clin Oncol.
1990 Jul;8(7):1199-206. doi: 10.1200/JCO.1990.8.7.1199. PubMed PMID:
1694236.
The repeated sequence CATT(A/T) is required for granulocyte-macrophage colony-stimulating factor promoter activity.
Mol Cell Biol.
1990 Nov;10(11):6084-8. doi: 10.1128/mcb.10.11.6084-6088.1990. PubMed PMID:
2233734; PubMed Central PMCID:
PMC361411.
Retention of graft-versus-leukemia using selective depletion of CD8-positive T lymphocytes for prevention of graft-versus-host disease following bone marrow transplantation for chronic myelogenous leukemia.
Transplant Proc.
1991 Feb;23(1 Pt 2):1695-6. PubMed PMID:
1899162.
Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy, and nervous system effects.
Ann Intern Med.
1991 Mar 1;114(5):402-16. doi: 10.7326/0003-4819-114-5-402. Review. PubMed PMID:
1992884.
Abdominal presentation of varicella-zoster infection in recipients of allogeneic bone marrow transplantation.
Bone Marrow Transplant.
1991 Jun;7(6):489-91. PubMed PMID:
1843181.
In vitro production of granulocyte-macrophage colony-stimulating factor in aplastic anemia: possible mechanisms of action of antithymocyte globulin.
Blood.
1991 Jul 1;78(1):163-8. PubMed PMID:
2070050.
Tax responsiveness of the GM-CSF promoter is mediated by mitogen-inducible sequences other than kappa B.
New Biol.
1991 Oct;3(10):997-1004. PubMed PMID:
1768653.
Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission.
J Clin Oncol.
1992 Jan;10(1):41-6. doi: 10.1200/JCO.1992.10.1.41. PubMed PMID:
1727924.
Production of granulocyte-macrophage colony-stimulating factor in two patients with lung cancer, leukocytosis, and eosinophilia.
Cancer.
1992 Mar 15;69(6):1342-6. doi: 10.1002/1097-0142(19920315)69:6<1342::aid-cncr2820690607>3.0.co;2-u. PubMed PMID:
1540871.
A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukaemia.
Br J Haematol.
1992 Jun;81(2):170-7. doi: 10.1111/j.1365-2141.1992.tb08203.x. PubMed PMID:
1643014.
The use of colony-stimulating factors in primary hematologic disorders.
Cancer.
1992 Aug 15;70(4 Suppl):921-7. Review. PubMed PMID:
1638464.
HTLV-I and HTLV-II tax trans-activate the human EGR-1 promoter through different cis-acting sequences.
Oncogene.
1992 Nov;7(11):2125-30. PubMed PMID:
1359492.
Transcription factors, translocations, and leukemia.
Blood.
1992 Dec 15;80(12):2953-63. Review. PubMed PMID:
1361370.
Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia.
Blood.
1992 Dec 15;80(12):2977-82. PubMed PMID:
1467513.
Phase II study of etoposide, ifosfamide, and mitoxantrone for the treatment of resistant adult acute lymphoblastic leukemia.
Am J Hematol.
1993 Jul;43(3):195-9. doi: 10.1002/ajh.2830430307. PubMed PMID:
8352235.
Use of recombinant GM-CSF following allogeneic BMTs for aplastic anemia.
Bone Marrow Transplant.
1993 Aug;12(2):173-5. PubMed PMID:
8401368.
Effect of induction cytarabine dose intensity on long-term survival in acute myelogenous leukemia: results of a randomized, controlled study.
Leuk Lymphoma.
1993 Sep;11(1-2):69-77. doi: 10.3109/10428199309054732. PubMed PMID:
8220156.
Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation. A randomized controlled trial.
Transplantation.
1994 Jan;57(1):82-7. doi: 10.1097/00007890-199401000-00015. PubMed PMID:
8291119.
Chronic myelogenous leukemia following repeated radiation therapy for histiocytosis X.
Leuk Lymphoma.
1994 Jan;12(3-4):315-6. doi: 10.3109/10428199409059604. PubMed PMID:
8167563.
Characterization of a cell-type-restricted negative regulatory activity of the human granulocyte-macrophage colony-stimulating factor gene.
Mol Cell Biol.
1994 Mar;14(3):2213-21. doi: 10.1128/mcb.14.3.2213-2221.1994. PubMed PMID:
8114751; PubMed Central PMCID:
PMC358581.
Phase I-II study of busulfan and cyclophosphamide conditioning for transplantation in advanced multiple myeloma.
Bone Marrow Transplant.
1994 Jul;14(1):131-6. PubMed PMID:
7951100.
A phase I/II study of interleukin-3 in patients with aplastic anemia and myelodysplasia.
Exp Hematol.
1994 Aug;22(9):875-80. PubMed PMID:
8062886.
An increased HLA DR2 frequency is seen in aplastic anemia patients.
Blood.
1994 Aug 1;84(3):923-7. PubMed PMID:
8043874.
Treatment of advanced acute leukaemia with allogeneic bone marrow transplantation from unrelated donors.
Br J Haematol.
1994 Sep;88(1):72-8. doi: 10.1111/j.1365-2141.1994.tb04979.x. PubMed PMID:
7803259.
Serum stem cell factor levels in patients with aplastic anemia.
Int J Hematol.
1994 Oct;60(3):185-9. PubMed PMID:
7532030.
Characterization of nuclear factors that bind to a critical positive regulatory element of the human granulocyte-macrophage colony-stimulating factor promoter.
Blood.
1994 Oct 15;84(8):2523-30. PubMed PMID:
7919370.
Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping.
Gene Expr.
1995;4(4-5):281-99. PubMed PMID:
7787419; PubMed Central PMCID:
PMC6134382.
Long-term outcome of aplastic anemia in adults treated with antithymocyte globulin: comparison with bone marrow transplantation.
Blood.
1995 Jan 1;85(1):283-90. PubMed PMID:
7803802.
A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia.
Blood.
1995 Jun 1;85(11):3066-76. PubMed PMID:
7538815.
What would you like to do?